Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas
NCT04334174 · University of Kansas Medical Center · PHASE2 · withdrawn · last registry update 2023-02-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “accrual not met” | – | Registry record, University of Kansas Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-01-23Phase 3 first posted: Stichting Hemato-Oncologie voor Volwassenen Nederland, Dexrazoxane + Rituximab (NCT06220032)
- 2024-01-05Phase 3 first posted: Genmab, Epcoritamab + Prednisone (NCT06191744)
- 2024-01-03Phase 3 first posted: National Research Center for Hematology, Russia, Cyclophosphamide + Doxorubicin Hydrochloride (NCT06188676)
- 2023-12-15Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT06172296)
- 2023-10-19Phase 3 first posted: Regeneron Pharmaceuticals, Odronextamab + Rituximab (NCT06091865)
- 2023-10-19Phase 3 first posted: Regeneron Pharmaceuticals, Odronextamab + Rituximab (NCT06091254)
- 2023-10-10Phase 3 first posted: Acrotech Biopharma Inc., Belinostat Injection + Pralatrexate Injection (NCT06072131)
- 2023-10-10Phase 3 first posted: BriaCell Therapeutics Corporation, SV-BR-1-GM + Cyclophosphamide (NCT06072612)
- 2023-09-21Phase 3 first posted: Hoffmann-La Roche, Glofitamab + Polatuzumab vedotin (NCT06047080)
- 2023-09-13Results posted on the registry: Astellas Pharma China, Inc., Enfortumab vedotin (NCT04995419)
- 2023-06-15Results posted on the registry: Daiichi Sankyo, Trastuzumab deruxtecan (DS-8201a) + Capecitabine (NCT03734029)
- 2023-05-31Results posted on the registry: National Cancer Institute (NCI), Bleomycin Sulfate + Brentuximab Vedotin (NCT02166463)
- 2023-04-20Phase 3 first posted: Universität des Saarlandes, R-miniCHOP + Acalabrutinib + R-miniCHOP (NCT05820841)
- 2023-04-14Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., SHR-A1811 + Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel (NCT05814354)
- 2023-02-24Results posted on the registry: St. Jude Children's Research Hospital, cyclophosphamide + topotecan (NCT01857934)
- 2023-01-25Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Dasatinib (NCT02143414)
- 2023-01-09Phase 3 first posted: National Cancer Institute (NCI), Bleomycin Sulfate + Brentuximab Vedotin (NCT05675410)
- 2022-12-28Results posted on the registry: Dana-Farber Cancer Institute, Eribulin + Adriamycin (NCT02623972)
- 2022-12-06Results posted on the registry: National Cancer Institute (NCI), Asparaginase + Blinatumomab (NCT02101853)
- 2022-10-13Phase 3 first posted: Genmab, Epcoritamab + Cyclophosphamide (NCT05578976)
- 2022-07-01Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin (NCT02306161)
- 2022-06-28Results posted on the registry: National Cancer Institute (NCI), Rituximab + Filgrastim (NCT00006436)
- 2022-05-19Phase 3 first posted: Children's Oncology Group, Cisplatin + Cyclophosphamide (NCT05382338)
- 2022-04-25Results posted on the registry: City of Hope Medical Center, everolimus + eribulin mesylate (NCT02120469)
- 2022-03-31Phase 3 first posted: Children's Oncology Group, Cyclophosphamide + Dactinomycin (NCT05304585)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision